Cargando…

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-one eligible patients received oxaliplatin 130 mg m(−2) intravenously on day 1 and capecitabine 1000 mg m(−2) orally twice daily on days 1 to 14 in a 21-day treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: van Meerten, E, Eskens, F A L M, van Gameren, E C, Doorn, L, van der Gaast, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360191/
https://www.ncbi.nlm.nih.gov/pubmed/17437008
http://dx.doi.org/10.1038/sj.bjc.6603750
_version_ 1782152987253145600
author van Meerten, E
Eskens, F A L M
van Gameren, E C
Doorn, L
van der Gaast, A
author_facet van Meerten, E
Eskens, F A L M
van Gameren, E C
Doorn, L
van der Gaast, A
author_sort van Meerten, E
collection PubMed
description This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-one eligible patients received oxaliplatin 130 mg m(−2) intravenously on day 1 and capecitabine 1000 mg m(−2) orally twice daily on days 1 to 14 in a 21-day treatment cycle as first-line treatment for advanced oesophageal cancer. Grade 3 neutropenia was seen in one patient and anaemia in another patient. No grade 4 haematological toxicities were observed. Grade 4 non-haematological toxicity (lethargy) occurred in one patient (2%). Grade 3 non-haematological toxicity was seen in 14 (27%) patients (vomiting and polyneuropathy (8%); nausea (6%); lethargy and hand–foot syndrome (4%); and anorexia, diarrhoea, and hyperbilirubinaemia (each in one patient)). In 22% of the patients, toxicity was the reason for stopping the treatment. The overall response rate was 39%. The median overall survival was 8 months; the 1-year survival rate was 26%. In the quality of life (QoL) analysis, the emotional well-being improved during treatment, but the physical functioning scores declined. The fatigue score on the symptom scales increased. Overall, the global QoL score did not change during treatment. In conclusion, the activity of oxaliplatin and capecitabine is comparable with other chemotherapy regimens in advanced oesophageal cancer with a low frequency of grade 3/4 toxicity. Because this treatment can be given on an outpatient basis, it is probably less toxic than cisplatin-based therapy and preserves QoL during treatment, it is a viable treatment option in patients with advanced oesophageal cancer.
format Text
id pubmed-2360191
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23601912009-09-10 First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study van Meerten, E Eskens, F A L M van Gameren, E C Doorn, L van der Gaast, A Br J Cancer Clinical Study This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-one eligible patients received oxaliplatin 130 mg m(−2) intravenously on day 1 and capecitabine 1000 mg m(−2) orally twice daily on days 1 to 14 in a 21-day treatment cycle as first-line treatment for advanced oesophageal cancer. Grade 3 neutropenia was seen in one patient and anaemia in another patient. No grade 4 haematological toxicities were observed. Grade 4 non-haematological toxicity (lethargy) occurred in one patient (2%). Grade 3 non-haematological toxicity was seen in 14 (27%) patients (vomiting and polyneuropathy (8%); nausea (6%); lethargy and hand–foot syndrome (4%); and anorexia, diarrhoea, and hyperbilirubinaemia (each in one patient)). In 22% of the patients, toxicity was the reason for stopping the treatment. The overall response rate was 39%. The median overall survival was 8 months; the 1-year survival rate was 26%. In the quality of life (QoL) analysis, the emotional well-being improved during treatment, but the physical functioning scores declined. The fatigue score on the symptom scales increased. Overall, the global QoL score did not change during treatment. In conclusion, the activity of oxaliplatin and capecitabine is comparable with other chemotherapy regimens in advanced oesophageal cancer with a low frequency of grade 3/4 toxicity. Because this treatment can be given on an outpatient basis, it is probably less toxic than cisplatin-based therapy and preserves QoL during treatment, it is a viable treatment option in patients with advanced oesophageal cancer. Nature Publishing Group 2007-05-07 2007-04-17 /pmc/articles/PMC2360191/ /pubmed/17437008 http://dx.doi.org/10.1038/sj.bjc.6603750 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
van Meerten, E
Eskens, F A L M
van Gameren, E C
Doorn, L
van der Gaast, A
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title_full First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title_fullStr First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title_full_unstemmed First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title_short First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
title_sort first-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase ii study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360191/
https://www.ncbi.nlm.nih.gov/pubmed/17437008
http://dx.doi.org/10.1038/sj.bjc.6603750
work_keys_str_mv AT vanmeertene firstlinetreatmentwithoxaliplatinandcapecitabineinpatientswithadvancedormetastaticoesophagealcanceraphaseiistudy
AT eskensfalm firstlinetreatmentwithoxaliplatinandcapecitabineinpatientswithadvancedormetastaticoesophagealcanceraphaseiistudy
AT vangamerenec firstlinetreatmentwithoxaliplatinandcapecitabineinpatientswithadvancedormetastaticoesophagealcanceraphaseiistudy
AT doornl firstlinetreatmentwithoxaliplatinandcapecitabineinpatientswithadvancedormetastaticoesophagealcanceraphaseiistudy
AT vandergaasta firstlinetreatmentwithoxaliplatinandcapecitabineinpatientswithadvancedormetastaticoesophagealcanceraphaseiistudy